These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 19451907

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS.
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract] [Full Text] [Related]

  • 3. Concerns raised over declining antiinfectives R&D.
    Fox JL.
    Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS.
    N Engl J Med; 2008 Nov 06; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. FDA not NIH can speed new drugs.
    Miller HI.
    Nature; 2011 Apr 14; 472(7342):169. PubMed ID: 21490657
    [No Abstract] [Full Text] [Related]

  • 11. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2009 Apr 14; 22(1):30-8. PubMed ID: 19209297
    [Abstract] [Full Text] [Related]

  • 12. In defence of priority review vouchers.
    Sonderholm J.
    Bioethics; 2009 Sep 14; 23(7):413-20. PubMed ID: 19659848
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. BIO and biogenerics.
    Feldbaum CB.
    Nat Biotechnol; 2005 Jan 14; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
    Davis C, Abraham J.
    Sociol Health Illn; 2011 Jul 14; 33(5):731-47. PubMed ID: 21314687
    [Abstract] [Full Text] [Related]

  • 20. Vouchers for FDA priority reviews.
    Spatz ID.
    Health Aff (Millwood); 2006 Jul 14; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.